TAG and a coalition of civil society activists, public health leaders, and researchers acting in solidarity with communities affected by tuberculosis sent an open letter to Johnson & Johnson calling on the company to publicly commit to withdraw and not…
Comment submitted prior to their meeting on November 17, 2022. Comment is in regard to discussion and voting on recommendation related to implementation of the HIV Organ Policy Equity (HOPE) Act of 2013, specifically pertaining to HIV-positive to HIV-positive organ transplantation and pertaining to the following draft recommendation under consideration regarding removal of the statutory “NIH Research Criteria and IRB” requirement.
On September 14, 2022, a coalition of activists, researchers, and public health professionals sent the following letter to the White House MPX Coordinators, OSTP, CDC, and NIH/NIAID asking for a coordinated and adequately funded comprehensive Federal research effort to contain,…
At the first of these two public hearings TAG submitted the following statement with six reasons why the new international instrument must explicitly acknowledge the right to science as a central guiding framework.
On February 9, TAG submitted this testimony to the Office of the High Commission for Human Rights (OHCHR) to inform its upcoming report to the Human Rights Council (HRC) on 'human rights in the context of HIV/AIDS' (HRC resolution 47/17).
In response to the Biden administration's intention to create a new research agency under the NIH called the Advanced Research Projects Agency for Health (ARPA-H), TAG and AVAC were invited to present remarks and guidance on the behalf of the Federal AIDS Policy Partnership and Research Work Group (RWG).
On June 24, TAG submitted testimony to the Senate Subcommittee on Labor, Health and Human Services, Education, and Related Agencies outlining funding priorities for fiscal year 2022.
TAG submitted comments in response to the National Institute of Standards and Technology's (NIST) proposed change to rulemaking, strongly opposing amendments to remove crucial public health safeguards from the Bayh-Dole Act. March-in rights and other provisions to hold manufacturers accountable when federally funded inventions are exorbitantly priced and are critically important to public health and the right to science.
TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for diagnostics as a global norm; and increasing investments in alternative rapid molecular tests to promote competition and improve access.
In March of 2021, the Tuberculosis Roundtable, of which TAG is a member organization, recently submitted letters to Congressional appropriators in support of increased funding for domestic and global TB programs for the 2022 fiscal year.